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Background: Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most
convincing predictive biomarker for temozolomide (TMZ) response in patients with glioblastoma multiforme (GBM).
However, technical obstacles prevent this biomarker from being applied widely. On the other hand, microRNAs
(miRNAs) are easily investigated in the clinical setting using quantitative real-time polymerase chain reactions. This
study aimed to identify miRNAs that could serve as predictive biomarkers for TMZ response.
Methods: The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases were used to
investigate the significance of associations between miRNA expression and overall survival (OS) in TMZ-treated
patients with GBM. Cytotoxicity assays were used to validate the miRNAs’ roles in the response of glioma cells to
TMZ. Biological insights concerning the miRNAs were explored using gene set enrichment analysis (GSEA) and gene
ontology (GO) analysis.
Results: miR-130a was found to be significantly associated with OS in TMZ-treated patients from TCGA and the
CGGA. In contrast, miR-130a appeared to be unassociated with OS in patients who only received radiotherapy. The
TMZ cytotoxicity assay showed that miR-130a over-expression could sensitize response to TMZ in glioma cells. GSEA
and GO analysis indicated that lower miR-130a could generate a more extensive response to oxidative stress, which
in turn could elevate Ape1 and mediate resistance to TMZ. In vitro experiment verified that cells with lower
miR-130a express higher Ape1 under oxidative stress.
Conclusions: Our data suggested that miR-130a could be a predictive marker for TMZ response in patients with
GBM, independently of the mechanism by which MGMT acts as a biomarker. miR-130a could serve as a guide for
treatment strategy selection in cases of GBM.
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Glioblastoma multiforme (GBM) is the most malignant
and common brain tumor in adults. Temozolomide
(TMZ) is currently the first-line chemotherapy for this
disease. TMZ can cross the blood–brain barrier and signifi-
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cause of resistance to TMZ. Biomarkers have been devel-
oped to predict patients’ responses to TMZ.
O6-methylguanine-DNA methyltransferase (MGMT)
promoter methylation is currently the most convincing
predictive biomarker for TMZ response, based on its
correlation with overall survival (OS) in patients with
GBM who have received TMZ chemotherapy [2-4]. However,
this biomarker remains unsuitable for guiding GBM
treatment in widespread application because of technical
obstacles [4].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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that are more stable than messenger RNAs. Since quan-
titative real-time polymerase chain reaction (qRT-PCR)
is widely used to quantify RNA expression levels in clin-
ical practice, it would be convenient to have a miRNA
that could be used to predict response to TMZ treat-
ment in patients with GBM. Previous studies [5-11] re-
ported several kinds of miRNAs which have predictive
value for TMZ response in glioblastoma. These studies
mainly focused on one special target of a miRNA. That
may not explain the whole function of the miRNA, since
one kind of miRNA can regulate hundreds of genes. Bio-
informatic analyses, on the other hand, could illustrate
the miRNA function from the macroscopic view. In this
study, using bioinformatic methods, we sought to iden-
tify such a miRNA, finding evidence that miR-130a is
correlated with OS in TMZ-treated patients with GBM.




The Cancer Genome Atlas (TCGA) database [12] in-
cluded miRNA expression profiling of 184 adult patients
who had GBM and underwent radiation therapy and
TMZ chemotherapy. Data on these patients were used
as a discovery set. We downloaded the mRNA expres-
sion profiling and clinical information on these patients,
as well as the miRNA expression profiling of another
128 glioblastoma patients in TCGA who only received
radiation therapy. Additionally, we obtained miRNA ex-
pression profiling of 28 adult patients who had glioblast-
oma and underwent TMZ chemotherapy from the
Chinese Glioma Genome Atlas (CGGA) database [13].
Data on these 28 patients were used as a validation set.
Cell culture
Human glioma cell lines U87, LN229, SHG44, and U251
were cultured in DMEM/F-12 culture medium (Gibco, Life
Technologies, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum (Gibco). Cells were maintained in a hu-
midified incubator with 5% CO2 at 37°C. The All-in-One
miRNA qRT-PCR Detection Kit (FulenGen, Guangzhou,
China) was used to evaluate the miR-130a levels in cells.
Transfection
Regarding miR-130a mimics and control miRNA, inhibi-
tors for miRNA-130a and controls were purchased from
FulenGen in China. Transfection was performed using
Lipofectamine RNAiMAX Transfection Reagent (Invi-
trogen, Life Technologies, Carlsbad, CA, USA), following
the manufacturer’s instructions. Transfection efficiency
was also evaluated using the All-in-One miRNA qRT-
PCR Detection Kit.TMZ cytotoxicity assay
After transfection, cells were seeded at a density of 6000
cells per well on 96 well plates in triplicates. TMZ
(Sigma Aldrich, St. Louis, MO, USA) was added at vari-
ous concentrations ranging from 0 to 1000 μmol/L for
48 hours. The Cell Titer 96 AQueous One Solution Cell
Proliferation Assay kit (Promega, Madison, WI, USA)
was used to determine the number of viable cells in the
TMZ cytotoxicity assay. To test the cleavage of nuclear
poly (ADP-ribose) polymerase (PARP), proteins of
SHG44 and U251 were extracted after transfection and
96 hours 500 μM TMZ treatment.
Induction of Oxidative Stress with hydrogen peroxide
At 48 hours after transfection, cells were washed twice
with PBS, then incubated in complete medium supple-
mented with 100 μM hydrogen peroxide to induce oxida-
tive stress. The incubation continued for 24 hours before
determination of Ape1 expression using western blotting.
Western Blotting
Proteins were extracted using RIPA buffer (Cell Signal-
ing Technology) supplemented with protease inhibitor.
Proteins were separated by 10% SDS-PAGE and trans-
ferred to PVDF membrane. After blocking with 5%
skim milk in TBST, the membranes were incubated
with primary antibodies overnight at 4°C. The mem-
branes were then washed and incubated with secondary
antibodies for 1 hour. Antibody binding was assessed
by enhanced chemiluminescence substrate (BioRad).
Antibodies to PARP and Ape1 were purchased from
Proteintech in China.
Statistical analysis
For each miRNA, the association between the expression
level and OS in the discovery set was calculated using a
univariate Cox proportional hazards regression analysis.
The 4 miRNAs that were found to be significantly asso-
ciated with OS in the discovery set were then evaluated
in the validation set using the Kaplan-Meier method and
2-sided log-rank tests. Subsequently, the miRNA that
was significantly associated with OS in both sets was
further analyzed using a Cox multivariate analysis that
included O-6-methylguanine-DNA methyltransferase
(MGMT) methylation status, age, and gender as covari-
ates. The association between the expression of this
miRNA and OS was also investigated in the group of
patients from TCGA who had received radiation ther-
apy alone. As previously, the Kaplan-Meier method and
2-sided log-rank tests were also used in this analysis.
The cutoff value for this miRNA in TCGA was defined
as the median expression level.
The miRNA-associated gene set was identified using a
Spearman correlation analysis. The negatively correlated
Table 1 miRNAs correlated with OS of patients treated
with temozolomide in TCGA
Variable Hazard ratio 95% CI p value
miR-130a 0.558 0.426–0.733 2.48 ∙ 10−5
miR-222 1.341 1.166–1.541 3.65 ∙ 10−5
miR-221 1.416 1.187–1.690 0.0001093
miR-20a 0.693 0.560–0.857 0.0007161
CI, confidence interval.
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that was performed using DAVID [14]; (National Institute
of Allergy and Infectious Diseases, Bethesda, MD, USA).
Additionally, we performed a Gene Set Enrichment Ana-
lysis (GSEA) with GSEA software downloaded from the
Broad Institute [15,16] (Cambridge, MA, USA).
Paired-sample t-tests were employed to assess the signifi-
cance of differences between TMZ cytotoxicity assay results.
Statistical analyses of TCGA and CGGA datasets were
performed using BRB-Array Tools 4.3.0 Beta_2, which
was developed by Dr. Richard Simon and the BRB-Array
Tools Development Team (National Cancer Institute,Figure 1 Kaplan-Meier estimates of overall survival. (A) Higher miR-130a
(TMZ)-treated glioblastoma multiforme(GBM) patients from The Cancer Genom
improved survival in TMZ-treated GBM patients from TCGA. (C) Higher miR-22
GBM patients from TCGA. (D) Higher miR-222 expression level was associated
(E) Higher miR-130a expression level was associated with improved survival in
(F) The miR-130a level was not correlated with overall survival in patients fromBethesda, MD, USA). Statistical analyses for in vitro ex-
perimental results were performed using SPSS 16.0
(IBM SPSS, Inc., Chicago, IL, USA). Two-sided p-values
less than 0.05 were regarded as statistically significant.
Results
miR-130a was correlated with overall survival in
TMZ-treated patients with GBM, but not in non-TMZ-
treated patients
Cox univariate analyses showed that miR-130a, miR-20a,
miR-221, and miR-222 were correlated with OS in
TMZ-treated patients with GBM from TCGA (Table 1,
Figure 1A,B,C and D). These 4 miRNAs were then eval-
uated in the validation dataset using the Kaplan-Meier
method and 2-sided log-rank tests. miR-130a was found
to be significantly correlated with OS in both of the
datasets (Figure 1E).
MGMT methylation status, age, and gender were ana-
lyzed using univariate Cox analyses. MGMT methyla-
tion status and age were found to be significantly
associated with OS (Table 2). miR-130a was then ana-
lyzed in the group of TMZ-treated GBM patients from
TCGA using a multivariate Cox analysis that includedexpression level was associated with improved survival in temozolomide
e Atlas (TCGA). (B) Higher miR-20a expression level was associated with
1 expression level was associated with decreased survival in TMZ-treated
with decreased survival in TMZ-treated GBM patients from TCGA.
TMZ-treated GBM patients from the Chinese Glioma Genome Atlas.
TCGA who did not receive treatment with TMZ.
Table 2 Cox regression analyses of the associations of miR-130a and clinical characteristics with OS in TCGA
Variable Univariate Cox regression Multivariate Cox regression
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
Gender 0.776 0.536–1.125 0.181
Age 1.027 1.012–1.042 0.001 1.016 0.998–1.035 0.088
MGMT methylation 0.559 0.361–0.864 0.009 0.654 0.413–1.008 0.054
miR-130a 0.558 0.426–0.733 0.000 0.665 0.473–0.935 0.019
CI, confidence interval; MGMT, O-6-methylguanine-DNA methyltransferase.
Figure 2 Biological insights regarding miR-130a. (A) Heat map of the gene expression signature correlated with miR-130a expression.
Columns represent patients and rows represent probes. Patients are ordered from left to right by increasing miR-130a expression. (B) The top
10 gene ontology terms for miR-130a negatively associated genes. (C) Gene set enrichment analysis showed enrichment of genes related to
response to oxidative stress among patients with low miR-130a expression. NES, normalized enrichment score. (D) SHG44 transfected with the scrambled
control (SHG44-SC) expressed higher Ape1 than cells transfected with miR-130a mimics (SHG44-M) did under oxidative stress. (E) U251 transfected with
the scrambled control (U251-SC) expressed lower Ape1 than cells transfected with miR-130a inhibitors (U251-I) did under oxidative stress.
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miR-130a remained significantly associated with OS in
this analysis.
Further, the Kaplan-Meier method and 2-sided log-
rank tests showed that miR-130a was not significantly
associated with OS in the patients who only received ra-
diation therapy (Figure 1F).Figure 3 miR-130a sensitized the response of glioma cells to temozol
cell lines. (B) SHG44 was transfected with miR-130a mimics (SHG44-M) and
sensitive to TMZ than SHG44-SC (p = 0.027). Overexpression of miR-130a inc
transfected with inhibitors for miR-130a (U251-I) and the scrambled contro
(p = 0.039). Knockdown of miR-130a decreased PARP cleavage in U251 induBiological insights regarding miR-130a
GO analysis and GSEA were conducted to provide
biological insights concerning the role of miR-130a.
The mRNA expression profiling data were used to find
miR-130a-correlated genes, as assessed using Spearman’s
correlation coefficient. The eighty-six genes (Figure 2A)
that were negatively correlated with miR-130a were thenomide (TMZ). (A) miR-130a level in 5 glioblastoma multiforme(GBM)
scrambled control miRNAs (SHG44-SC). (C) SHG44-M were more
reased PARP cleavage in SHG44 induced by TMZ. (D) U251 was
l (U251–SC). (E) U251-I were more resistant to TMZ than U251–SC
ced by TMZ.
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sented in Figure 2B. As shown in the figure, miR-130a-
related genes had a relatively tight association with oxidation
reduction.
In addition, GSEA showed enrichment of genes related
to response to oxidative stress (ROS) among patients
with low miR-130a expression (normalized enrichment
score [NES] =1.51, p = 0.037).
The miR-130a levels were relatively low in SHG44
cells (Figure 3A). This cell line was then transfected with
miR-130a mimics and the scrambled control (Figure 3B).
Western blotting showed that SHG44 transfected with the
scrambled control (SHG44-SC) expressed higher Ape1
than cells transfected with miR-130a mimics (SHG44-M)
did under oxidative stress (Figure 2D).
The miR-130a levels were relatively high in U251 cells
(Figure 3A). This cell line was then transfected with inhibi-
tors (5′-AUGCCCUUUUAACAUUGCACUG-3′) for miR-
130a and the scrambled control (Figure 3D). Western
blotting showed that U251 transfected with the scrambled
control (U251-SC) expressed lower Ape1 than cells trans-
fected with miR-130a inhibitors (U251-I) did under oxida-
tive stress (Figure 2E).
miR-130a over expression sensitized the response of
glioma cells to TMZ
The TMZ cytotoxicity assay showed that SHG44-M
were more sensitive to TMZ than SHG44-SC (p = 0.027,Figure 4 Lower miR-130a could generate more extensive response to
of abasic sites. In double-stranded DNA, N7-methylguanine (7-meG),
accounts for approximately 70, 10, and 7% of temozolomide (TMZ)-indu
O6-methylguanine-DNA methyltransferase (MGMT). 7-meG and 3-meA c
Apurinic/apyrimidinic endonuclease 1 (Ape1) is the key enzyme that remov
extensive response to oxidative stress, which in turn could elevate Ape1 anFigure 3C). Western blotting showed that overexpression
of miR-130a increased PARP cleavage in SHG44 induced
by TMZ (Figure 3C).
U251-I were found to be more resistant to TMZ than
U251-SC (p = 0.039, Figure 3E). Western blotting showed
knockdown of miR-130a decreased PARP cleavage in
U251 induced by TMZ (Figure 3E).Discussion
In our univariate Cox analyses of TCGA data, miR-130a,
miR-20a, miR-221, and miR-222 showed significant asso-
ciations with the OS of patients with GBM who received
TMZ chemotherapy. However, only the predictive cap-
acity of miR-130a was validated by an analysis of CGGA
data on patients with GBM who received TMZ chemo-
therapy. In a further analysis of TCGA data, we also ob-
served that miR-130a failed to correlate with the OS of
patients with GBM who received radiation therapy alone.
The role of miR-130a in the chemo-resistance of
GBM cells was also determined in the present study.
SHG44 with up-regulated miR-130a showed higher sen-
sitivity than parental cells. On the other hand, U251
with down-regulated miR-130a showed lower sensitivity
than parental cells. The cytotoxicity of TMZ was less
than 50% in these investigations because of the short
duration of treatment. Further in vitro functional re-
search on miR-130a is necessary.oxidative stress, which in turn could elevate Ape1 and the repair
N3-methyladenine (3-meA) and O6-methylguanine (O6-meG)
ced DNA adducts, respectively. O6-meG adduct is repaired by
ould generate abasic sites, which can impede DNA replication.
es abasic sites. Patients with lower miR-130a could generate a more
d the repair of abasic sites, finally mediating resistance to TMZ.
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with prolonged OS in patients who had GBM and received
TMZ chemotherapy. miR-130a could be a candidate pre-
dictive biomarker for TMZ response.
miR-130a has been reported to reduce resistance to Gefi-
tinib and TNF-related apoptosis-inducing ligand (TRAIL)
in Non-small cell lung cancer by down-regulating MET
and miRNA-221/222 [17,18]. To investigate the biological
mechanism of miR-130a in GBM, we performed GSEA
and GO analysis of miR-130a-associated genes. Oxidation
reduction and ROS were showed to be involved in miR-
130a-correlated biological processes.
MGMT promotes clinical resistance to chemotherapy
through its ability to remove the O6-methylguanine (O6-
meG) adduct produced by TMZ [19,20]. In fact, TMZ also
generates several other kinds of DNA adducts in cells. N7-
methylguanine (7-meG) and N3-methyladenine (3-meA)
are the most abundant of these DNA adducts [4]. They are
precursors of abasic sites, which can impede DNA replica-
tion [21-23]. The base excision repair (BER) pathway is re-
sponsible for repairing these lesions. Apurinic/apyrimidinic
endonuclease 1 (Ape1) is the key enzyme in BER pathways
that remove abasic sites induced by TMZ [24,25]. The
function of Ape1, which is independent of MGMT, can lead
to cell resistance to TMZ treatment [26]. A small-molecule
inhibitor of Ape1 has been found to block proliferation and
reduces viability of glioblastoma cells [27]. It has been
reported that oxidative stress could elevate Ape1, which in
turn mediates chemoresistance by repairing abasic sites
produced by TMZ [28,29].
GO analysis and GSEA showed a negative correlation
between response to oxidation stress and miR-130a.
Patients with lower miR-130a expression possess a higher
ability to respond to oxidative stress. In the present study,
we found that cells with lower miR-130a could express
higher Ape1 under oxidative stress. Several factors could
induce oxidative stress in glioma, including seizures [30],
angiogenesis associated nitric oxide [31], surgery associ-
ated inflammation, and radiotherapy-delivered reactive
oxygen species. We hypothesize that, in the presence of
these factors, patients with lower miR-130a could generate
a more extensive response to oxidative stress, which in
turn could elevate Ape1 and the repair of abasic sites,
finally mediating resistance to TMZ (Figure 4). Because
Ape1-repaired DNA adducts are different from O6-mG,
this process is independent of MGMT. It appears that
miR-130a was an even better predictive marker than
MGMT methylation in the present study, since the former
was significantly correlated with OS in a multivariate Cox
analysis, while the latter was not (Table 2).
Conclusions
In summary, we have reported that miR-130a could be
a predictive marker for TMZ response in patients withGBM, and that this predictive ability is independent of the
predictive ability of MGMT. Further, the miR-130a bio-
marker is more convenient to test than MGMT methyla-
tion. Its application could provide guidance when selecting
treatment strategies for GBM in the future.
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